Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1619 1648 1671
This examiner grants 74% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19295239 | THERMOSTABLE MUCOSAL VACCINE COMPOSITIONS AND METHODS | Final Rejection | GLOBAL HEALTH SOLUTIONS, INC. |
| 18024542 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 17914735 | REVERSE GENETIC SYSTEM FOR SARS-COV-2 | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18977008 | VACCINES COMPRISING METHANOBREVIBACTER GOTTSCHALKII | Non-Final OA | Arkea Bio Corp. |
| 18279314 | METHODS AND COMPOSITIONS FOR DETECTING AND PRODUCING PORCINE MORBILLIVIRUS AND VACCINES THEREOF | Non-Final OA | Iowa State University Research Foundation, Inc. |
| 18557987 | VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS | Non-Final OA | PFIZER INC. |
| 17771736 | IMPROVED VACCINES FOR RECURRENT RESPIRATORY PAPILLOMATOSIS AND METHODS FOR USING THE SAME | Non-Final OA | Inovio Pharmaceuticals, Inc. |
| 18064482 | LARGE AND SMALL T ANTIGENS OF MERKEL CELL POLYOMAVIRUS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME | Non-Final OA | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY |
| 18295675 | IMMUNOGENIC COMPOSITION USEFUL FOR VACCINATION AGAINST ROTAVIRUS | Final Rejection | BOEHRINGER INGELHEIM VETMEDICA GMBH |
| 18501677 | RECOMBINANT RSV VACCINE: METHODS OF MAKING AND USING THE SAME | Non-Final OA | BLUE LAKE BIOTECHNOLOGY, INC. |
| 18283130 | METHOD OF ELICITING AN IMMUNE RESPONSE AGAINST RESPIRATORY SYNCYTIAL VIRUS | Non-Final OA | CODAGENIX INC. |
| 18246304 | METHODS OF PRODUCING EXTRACELLULAR VESICLES | Non-Final OA | LONZA SALES AG |
| 18546427 | GENETICALLY MODIFIED CLOSTRIDIUM STRAINS EXPRESSING RECOMBINANT ANTIGENS AND USES THEREOF | Non-Final OA | LIVINGMED BIOTECH S.R.L. |
| 18245233 | COMPOSITIONS AND METHODS TARGETING FILAMENTOUS BACTERIOPHAGE | Final Rejection | INIMMUNE CORPORATION |
| 18043631 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | Non-Final OA | Sporegen Limited |
| 18041883 | SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS [SARS-CoV-2]-VIRUS-LIKE PARTICLE [VLP] VACCINE: COMPOSITIONS, DELIVERY STRATEGIES, METHODS AND USES | Non-Final OA | TECHNOVAX, INC. |
| 18007036 | MODIFIED CHIKUNGUNYA VIRUSES AND SINDBIS VIRUSES AND USES THEREOF | Non-Final OA | Replicate Bioscience, Inc. |
| 18016137 | LIVE-ATTENUATED VIRUS VACCINE | Non-Final OA | INDIAN IMMUNOLOGICALS LIMITED |
| 18003056 | COMBINATION PORCINE VACCINE | Final Rejection | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. |
| 17735019 | PARTICLES FOR STIMULATING AN IMMUNE RESPONSE AGAINST VIRAL INFECTIONS | Final Rejection | FINNCURE OY |
| 17631845 | A METHOD OF ELICITING AN IMMUNE RESPONSE BY ADMINISTERING A POPULATION OF POLYMERSOMES HAVING AN ASSOCIATED ANTIGEN TOGETHER WITH A POPULATION OF POLYMERSOMES HAVING AN ASSOCIATED ADJUVANT AS WELL AS COMPOSITIONS COMPRISING THE TWO POPULATIONS OF POLYMERSOMES | Final Rejection | ACM BIOLABS PTE LTD |
| 17539667 | PSORALEN-INACTIVATED CORONAVIRUS VACCINE AND METHOD OF PREPARATION | Non-Final OA | The United States of American as Represented by the Secretary of the Navy |
| 17324756 | Manufacture of Virus | Non-Final OA | KaliVir Immunotherapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy